BSX

Boston Scientific
D

BSX

Arincen84/100B

Boston Scientific balance sheet 1991–2026

Boston Scientific had 609.00M USD in cash and short-term investments on 30 September 2026, against total debt of 11.95B USD: net debt of 11.34B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
609.00M2.05B414.00M865.00M928.00M1.93B1.73B217.00M146.00M188.00M196.00M
Short-term investments
0.000.000.000.000.000.000.000.000.000.000.00
609.00M2.05B414.00M865.00M928.00M1.93B1.73B217.00M146.00M188.00M196.00M
Cash growth
-52.24%+393.96%-52.14%-6.79%-51.79%+11.02%+699.08%+48.63%-22.34%-4.08%-38.56%
Receivables
3.11B2.93B2.56B2.23B1.97B1.78B1.53B1.83B1.61B1.55B1.47B
Inventory
3.32B2.94B2.81B2.48B1.87B1.61B1.35B1.58B1.17B1.08B955.00M
Other current assets
1.13B580.00M831.00M622.00M731.00M799.00M1.88B880.00M922.00M942.00M541.00M
Total current assets
8.16B8.79B6.92B6.51B5.76B6.32B6.69B4.70B4.00B3.82B3.24B
Property, plant and equipment
4.18B4.50B3.74B3.30B2.83B2.69B2.54B2.42B1.78B1.70B1.63B
Long-term investments
2.29B842.00M555.00M413.00M407.00M412.00M918.00M458.00M-328.00M-191.00M-75.00M
Goodwill and intangibles
25.60B25.30B23.77B20.39B18.82B18.11B15.87B18.06B14.28B12.84B12.56B
Goodwill
18.74B18.28B17.09B14.39B12.92B11.99B9.95B10.18B7.91B7.00B6.68B
Intangible assets
6.86B7.02B6.68B6.00B5.90B6.12B5.92B7.89B6.37B5.84B5.88B
Other non-current assets
1.39B559.00M749.00M680.00M707.00M563.00M545.00M735.00M932.00M688.00M666.00M
Total assets
45.46B43.67B39.40B35.14B32.47B32.23B30.78B30.57B21.00B19.04B18.10B
Accounts payable
1.25B1.14B960.00M942.00M862.00M794.00M513.00M542.00M349.00M530.00M447.00M
Deferred revenue
0.00313.00M306.00M266.00M220.00M208.00M138.00M144.00M328.00M191.00M75.00M
Short-term debt
1.04B389.00M1.78B531.00M20.00M261.00M13.00M1.42B2.25B1.80B64.00M
Other current liabilities
3.69B2.17B491.00M1.92B1.64B629.00M1.17B861.00M2.03B2.73B2.50B
Total current liabilities
5.98B5.44B6.40B4.93B3.80B4.27B3.68B4.87B5.26B5.65B3.59B
Long-term debt
10.91B11.46B8.84B8.57B8.91B8.80B9.12B8.59B4.80B3.82B5.42B
Other non-current liabilities
2.43B1.14B1.14B1.27B1.40B1.55B1.66B2.36B1.88B2.37B2.34B
Lease obligations, current
0.000.000.000.000.000.000.000.000.000.000.00
Lease obligations, long-term
0.00571.00M527.00M395.00M352.00M395.00M408.00M282.00M0.001.00M1.00M
Total liabilities
19.59B19.20B17.39B15.61B14.90B15.61B15.45B16.69B12.27B12.03B11.36B
Common stock and paid-in capital
18.00M17.00M17.00M17.00M17.00M17.00M17.00M16.00M16.00M16.00M19.00M
Retained earnings
8.40B5.57B2.67B819.00M-750.00M-1.39B-2.38B-2.25B-6.95B-8.39B-8.58B
Accumulated other comprehensive income
-351.00M-610.00M275.00M49.00M269.00M263.00M207.00M270.00M33.00M-59.00M1.00M
Shareholders' equity
25.63B24.23B21.77B19.28B17.57B16.62B15.33B13.88B8.73B7.01B6.73B
Minority interest
243.00M239.00M233.00M248.00M0.000.000.000.000.000.000.00
11.95B11.85B11.15B9.49B9.28B9.45B9.54B10.28B7.03B5.58B5.48B
Net cash
-11.34B-9.80B-10.73B-8.63B-8.35B-7.53B-7.81B-10.06B-6.88B-5.39B-5.29B
Working capital
2.18B3.36B521.00M1.58B1.96B2.04B3.01B-167.00M-1.26B-1.83B-348.00M
Book value per share
17.6516.2114.6513.1812.2111.5910.829.846.235.034.89
Tangible book value
34.00M-1.07B-2.00B-1.11B-1.25B-1.49B-540.00M-4.19B-5.56B-5.82B-5.83B
Tangible book value per share
0.02-0.72-1.35-0.76-0.87-1.04-0.38-2.97-3.97-4.18-4.23
Current ratio
1.361.621.081.321.511.481.820.970.760.680.90
Debt to equity
0.470.490.510.490.530.570.620.740.810.800.81

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Boston Scientific's cash and debt

Source: Financial Modeling Prep